Skip to content

Resuscitation Quick Actions • First 2 Minutes

High-Acuity

30-Minute Analgesia Target

Administer first dose of parenteral opioid within 30-60 minutes of arrival; re-evaluate and re-dose every 15-30 minutes

Acute Chest Syndrome Triad

New pulmonary infiltrate on CXR + (Fever >= 38.5°C, Chest pain, Tachypnea, or SpO2 drop > 3% from baseline)

ACS Antimicrobials

Ceftriaxone 2g IV daily (or Cefotaxime) PLUS Azithromycin 500mg IV daily (covers atypicals: Chlamydia & Mycoplasma)

Exchange Transfusion Trigger

PaO2 < 60 mmHg, persistent SpO2 < 90% on high-flow O2, bilateral infiltrates, or stroke -> Stat Exchange targeting HbS < 30%

Splenic Sequestration Trap

Transfuse conservatively in small aliquots (5-10 mL/kg); do NOT transfuse beyond Hb 9-10 g/dL (causes fatal hyperviscosity)

Bottom-Line Clinical Pearl

Acute Chest Syndrome (ACS) is the leading cause of mortality in sickle cell disease; suspect ACS in any patient with fever, respiratory distress, or chest pain even if initial chest radiography is clear. Initiate broad-spectrum antibiotics, incentive spirometry, and prompt hematology consultation for emergent Red Blood Cell Exchange Transfusion (erythrocytapheresis) when PaO2 drops below 60 mmHg or multilobar infiltrates develop, targeting an HbS level < 30%.

1. Vaso-Occlusive Bone Crisis (VOC): Protocolized Analgesia

Vaso-occlusive crisis is caused by hypoxia, acidosis, dehydration, or hypothermia promoting the polymerization of deoxygenated sickle hemoglobin (HbS). Rigid, crescent-shaped erythrocytes obstruct the microcirculation, creating localized bone marrow ischemia, bone infarction, and intense inflammatory pain. The National Heart, Lung, and Blood Institute (NHLBI) guidelines mandate rapid, individualized analgesia:

Phase/InterventionClinical Target & PharmacotherapyPhysiological Pearl & High-Yield Pitfall
First-Line Rapid Opioid DeliveryAdminister initial parenteral opioid dose WITHIN 30 MINUTES OF ARRIVAL: - Morphine 0.1 mg/kg IV (or SC) OR - Hydromorphone (Dilaudid) 0.02 mg/kg IV (1–2 mg IV). Re-evaluate and re-dose every 15 to 30 minutes until pain score decreases by >= 50%.Under-treatment of pain is widespread due to clinician bias. Rely on patient self-reported pain and home opioid tolerance regimens rather than vital signs (patients in severe chronic pain often adapt without tachycardia).
Multimodal Non-Opioid Adjuncts1. Ketorolac (Toradol) 15 mg IV every 6 hours (max 5 days; verify baseline renal function). 2. Acetaminophen 1,000 mg IV or PO every 6 hours. 3. Low-dose sub-dissociative Ketamine (0.1–0.3 mg/kg IV over 15 min) for refractory pain.NSAIDs reduce bone marrow prostaglandin synthesis and decrease opioid requirements by 30-40%. Avoid Meperidine (Demerol) entirely: accumulation of normeperidine metabolite causes CNS excitation, tremors, and seizures.
Hydration & Incentive Spirometry1. Euvolemic hydration: D5 0.45% Normal Saline at maintenance rate (NOT massive fluid boluses). 2. Incentive Spirometry: 10 maximal breaths every 2 hours while awake.Over-hydration is dangerous: aggressive fluid boluses cause iatrogenic pulmonary edema and worsen atelectasis, directly precipitating Acute Chest Syndrome. Incentive spirometry reduces ACS incidence by > 50%.

2. Acute Chest Syndrome (ACS): Diagnosis & Exchange Transfusion

Acute Chest Syndrome is the most frequent cause of acute clinical deterioration and death in adolescents and adults with SCD. It is defined as a new radiodensity on chest radiograph accompanied by fever, respiratory symptoms, or hypoxemia:

Clinical DomainDiagnostic Features & PathophysiologyEmergency Action & Treatment Protocol
Diagnostic CriteriaNew pulmonary segmental infiltrate on CXR PLUS at least ONE of the following: 1. Fever >= 38.5°C 2. Chest pain 3. Tachypnea, intercostal retractions, or wheezing 4. Drop in SpO2 > 3% from baseline (or PaO2 < 60 mmHg).Early CXR may be completely normal during the first 24-48 hours. Any sickle cell patient with fever and chest pain or tachypnea must be admitted and treated presumptively for evolving ACS.
Antimicrobial TherapyPolymicrobial etiology: - Atypical pathogens (Chlamydia pneumoniae, Mycoplasma) - Typical encapsulated bacteria (Streptococcus pneumoniae) - Bone marrow pulmonary fat embolism.Empiric Dual Coverage: 1. Ceftriaxone 2g IV daily (or Ampicillin-Sulbactam 3g IV q6h) PLUS 2. Azithromycin 500 mg IV daily (covers atypicals) Add Vancomycin (15-20 mg/kg IV) if patient is critically ill or MRSA is prevalent.
Simple Transfusion vs. Exchange TransfusionSimple PRBC Transfusion: Indicated for mild-to-moderate ACS with Hb drop > 1-2 g/dL below baseline. Emergent Automated Red Cell Exchange (Erythrocytapheresis): Indicated for severe ACS (PaO2 < 60 mmHg, bilateral/multilobar infiltrates, deteriorating hemodynamics, or acute stroke).TARGETS FOR EXCHANGE: 1. Reduce HbS concentration to < 30% 2. Maintain total Hemoglobin at 10 g/dL (hematocrit ~30%). Never transfuse total Hb > 10–11 g/dL, as hyperviscosity precipitates catastrophic vaso-occlusive stasis and stroke!

3. Splenic Sequestration & Aplastic Crises

Crisis TypeEtiology & Age GroupLaboratory ProfileEmergency Management
Acute Splenic Sequestration CrisisVaso-occlusion of splenic outflow vessels traps up to 50% of the circulating red cell mass within the splenic red pulp. Occurs in infants and young children (< 5 years) before autosplenectomy.1. Sudden drop in Hemoglobin by > 2.0 g/dL below baseline 2. Profound compensatory RETICULOCYTOSIS (> 15-20%) 3. Thrombocytopenia 4. Massive, exquisitely tender, firm splenomegaly 5. Hypovolemic shock.Emergent Resuscitation: 1. Cautious IV crystalloid boluses (10-20 mL/kg) 2. Small-volume PRBC transfusion (5–10 mL/kg). CRITICAL CAUTION: Transfuse ONLY to restore hemodynamic stability (target Hb 7–8 g/dL). As splenic pooling resolves, trapped red cells re-enter the general circulation ('autotransfusion'); aggressive transfusion leads to fatal hyperviscosity syndrome and heart failure.
Aplastic CrisisTransient total arrest of bone marrow erythropoiesis triggered by Human Parvovirus B19 infection, which selectively infects and destroys erythroid progenitor cells in bone marrow.1. Severe, life-threatening drop in Hemoglobin (often < 3-4 g/dL) 2. PROFOUND RETICULOCYTOPENIA (< 0.5% or < 10,000/mcL) 3. Spleen is normal size (not enlarged) 4. Normal platelet and white blood cell counts.Immediate PRBC Transfusion: Transfuse packed red cells slowly (10 mL/kg) to restore oxygen-carrying capacity. Maintain respiratory isolation (droplet precautions). Erythropoiesis spontaneously resumes within 7 to 10 days.

Acute Chest Syndrome & The Hyperviscosity Transfusion Trap

Acute Chest Syndrome is the terminal event in over 50% of adult sickle cell deaths. When transfusing red blood cells in SCD (whether for ACS, splenic sequestration, or stroke), NEVER transfuse beyond a target Hemoglobin of 10.0 to 10.5 g/dL (Hematocrit ~30%). Sickled red blood cells have markedly abnormal rheology; raising the hematocrit above 30% without first removing HbS-containing cells causes a catastrophic, exponential increase in whole-blood viscosity. This precipitates widespread microvascular sludge, massive stroke, and circulatory arrest. For severe ACS or acute neurological deficits, the definitive procedure is Emergent Automated Erythrocytapheresis (Exchange Transfusion), which replaces HbS blood with normal HbA donor blood while maintaining total Hb at 10 g/dL.

Board & Shelf Drill 5 Questions • Untimed Tutor Mode

Test Your Sickle Cell Disease & Acute Vaso-Occlusive Crises Clinical Acumen

Directly launch an active-recall practice block from our 8,400+ validated COMLEX Level 1, 2-CE & 3 board question bank with complete explanations.